Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 2004

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

Cycle control, quality of life and acne with two low-dose oral

contraceptives containing 20 micrograms of ethinylestradiol.

AUTHORS

Winkler UH; Ferguson H; Mulders JA

SOURCE

Contraception. 2004 Jun;69(6):469-476.

ABSTRACT

Poor cycle control and tolerability can be reasons for irregular pill intake. This study compared the tolerability of two

low-dose oral contraceptives and their effect on cycle control. In this open, group-comparative, randomized

multicenter trial in Germany and the Netherlands, women received either 20 µg ethinylestradiol plus 150 µg

desogestrel (20EE/DSG; n = 500) or 20 µg ethinylestradiol plus 100 µg levonorgestrel (20EE/LNG; n = 498) for six

treatment cycles. Cycle control, dysmenorrhea and premenstrual syndrome (PMS) were assessed using diary cards.

Tolerability was assessed using the self-administered questionnaires Psychological General Well-Being Index

(PGWBI) and the Profile of Mood States (POMS). Acne was assessed by objective (acne counts) and subjective (no,

moderate, mild, severe) acne scoring of the facial area at baseline and treatment cycles 1, 3 and 6. A total of 404

(78.1%) and 384 (75.3%) women in the 20EE/DSG and 20EE/LNG groups, respectively, completed the trial. The

occurrence rate of irregular bleeding and spotting was statistically significantly higher with 20EE/LNG than with

20EE/DSG (0.18 vs. 0.13; p < 0.05). The mean number of bleeding-spotting days per cycle was statistically

significantly higher with 20EE/LNG than with 20EE/DSG (0.63 vs. 0.48; p < 0.05). Early withdrawal bleeding was more

frequent with 20EE/LNG (0.15 vs. 0.08; p < 0.005), whereas continued withdrawal bleeding was more frequent with

20EE/DSG (0.32 vs. 0.45; p < 0.001); absence of withdrawal bleeding was comparable (0.06 vs. 0.04, respectively).

Thirteen subjects in the 20EE/LNG group and three in the 20EE/DSG group discontinued due to unacceptable

bleeding (p < 0.05). Dysmenorrhea and PMS decreased comparably in both groups. There were no differences

between groups for the mean total scores of PGWBI or POMS at all time-points. Fewer acne lesions were counted

with 20EE/DSG vs. 20EE/LNG after six cycles (p < 0.05). The subjective acne scores supported this finding.

20EE/DSG provided better cycle control than 20EE/LNG with less treatment discontinuation due to unacceptable

bleeding. There were no apparent differences between the two groups regarding tolerability and quality of life. There

was less acne with 20EE/DSG. (PubHealth.info Document ID: CONT1T 519-06)

PubHealth.info NOTE: The author(s) of this article titled, "Cycle control, quality of life and acne with two low-dose

oral contraceptives containing 20 micrograms of ethinylestradiol.", is(are) Winkler UH; Ferguson H; Mulders JA.

The source of this article is "Contraception. 2004 Jun;69(6):469-476.". This article was published in 2004 in English

language(s). (PubHealth.info® Document ID: CONT1T 519-06. All rights reserved with PubHealth.info) PIN: 519

This article is peer-reviewed.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.